
SLNO
USDSoleno Therapeutics Inc. Common Stock
リアルタイム価格
価格チャート
主要指標
市場指標
始値
$74.240
高値
$74.270
安値
$72.780
出来高
0.05M
企業ファンダメンタルズ
時価総額
3.7B
業種
バイオテクノロジー
国
United States
取引統計
平均出来高
1.19M
取引所
NCM
通貨
USD
52週レンジ
AI分析レポート
最終更新: 2025年4月18日SLNO (Soleno Therapeutics Inc.): Analyzing Recent Moves & What Might Come Next
Stock Symbol: SLNO Generate Date: 2025-04-18 17:56:26
Alright, let's take a look at Soleno Therapeutics (SLNO). For anyone not glued to stock tickers, this is a biotech company focused on rare diseases. Recent news and price action have been pretty interesting, so let's break it down without the Wall Street jargon.
Recent News Buzz: Feeling Pretty Good
What's the vibe around Soleno lately? Strongly positive, it seems. Almost all the news is analysts saying "Buy!" and bumping up their price targets. We're talking firms like HC Wainwright, Stifel, Guggenheim, Laidlaw, Baird, and Cantor Fitzgerald – not exactly small names. They're not just saying "maybe it's okay"; they're actively recommending buying the stock.
Why the sudden love? Two big things jump out. First, the FDA approved their drug VYKAT™ XR for Prader-Willi Syndrome. This is huge – it's the first approved treatment for a key symptom of this rare condition. That's a major win for the company and, more importantly, for patients. Second, analysts are consistently raising their price targets, some even to $100 or higher. This suggests they believe the FDA approval and the drug launch are going to be big drivers for Soleno's value. So, the news is definitely painting a bright picture right now.
Price Check: Upward Momentum, But With Bumps
Let's peek at the stock chart. Over the last month or so, SLNO's price has been on a bit of a wild ride, but generally trending upwards. If you look back to late February, the price was in the mid-$40s. Then, BAM! Around late March, coinciding with the FDA approval news, the stock price jumped – we're talking a significant leap. It shot up into the $70s pretty quickly.
Since then, it's been bouncing around a bit in the high $60s and low $70s. Currently, it's hovering around $70. Compared to the earlier part of the period, it's clearly in a much higher range. Now, what about the AI predictions? They're forecasting slight, steady increases over the next few days, but nothing explosive. However, those analyst price targets we talked about earlier? They are significantly higher than the current price, suggesting analysts see a lot more room to run than the AI's short-term view.
Outlook & Ideas: Leaning Bullish, But Watch Closely
Putting it all together, what's the takeaway? Right now, the situation seems to favor potential buyers. The overwhelmingly positive news sentiment, driven by the FDA approval and analyst upgrades, combined with the recent price jump, suggests there's upward momentum.
If you're considering getting in, a potential entry point might be around the current price level, say in the $69-$71 range. Why there? Well, it's been acting as a bit of a consolidation area after the big jump, suggesting some support around this level. Of course, no guarantees in the stock market!
What about taking profits or managing risk? For a potential profit target, you could look at some of those analyst price targets. The $80-$100 range seems to be a common area they're pointing to. For risk management, setting a stop-loss is always a smart move. Perhaps somewhere below the recent lows, maybe around $65 or even a bit lower, could be a level to consider. This is just to protect yourself if the positive momentum stalls or reverses.
Important Context: Remember, Soleno is in the biotech sector. Drug approvals are massive catalysts for these companies. This FDA approval for VYKAT™ XR is a game-changer for them, and the market is reacting accordingly. Keep an eye on news related to the drug launch and how it's being received.
In short: Things look pretty positive for SLNO right now. Analysts are bullish, the news is good, and the price has shown strong upward movement. However, the stock market is never a straight line. Keep an eye on how things develop, especially around the drug launch, and always manage your risk.
Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. I am providing an interpretation of publicly available data, not recommending specific trades. Investing in the stock market involves risk, and you could lose money. Always conduct your own thorough research or consult with a qualified financial advisor before making any investment decisions.
関連ニュース
Piper Sandler Maintains Overweight on Soleno Therapeutics, Raises Price Target to $145
Piper Sandler analyst Yasmeen Rahimi maintains Soleno Therapeutics with a Overweight and raises the price target from $93 to $145.
HC Wainwright & Co. Reiterates Buy on Soleno Therapeutics, Maintains $100 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Soleno Therapeutics with a Buy and maintains $100 price target.
Soleno Therapeutics Announces VYKAT(TM) XR Launch
REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
AI予測Beta
AI推奨
更新日時: 2025年4月27日 23:50
60.3% 信頼度
リスクと取引
エントリーポイント
$73.27
利確
$80.26
損切り
$65.95
主要因子
関連株式
最新情報を入手
価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。